- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06065657
Effect of Nutritional Ketosis on Alcohol Metabolism (KAM)
January 22, 2024 updated by: University of Pennsylvania
The research study is being conducted in health controls to better understand the effects of ketosis on brain functioning after 3 different, randomly assigned, 3-day dietary interventions and the acute effects of alcohol after consuming about 4-5 alcohol beverages.
The labs visits will use magnetic resonance imaging (MRI) scans to study the brain, measuring levels of nicotinamide adenine dinucleotide (NAD), lactate, neurotransmitters glutamate, and Gamma-aminobutyric acid (GABA).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol.
Healthy participants will undergo three randomly assigned dietary interventions, each lasting three days, followed by a study lab visit day on day 4.
The three interventions are: (1) Eat a ketogenic diet for 3 days, (2) eat a control diet for 3 days with a ketone supplement drink, and (3) eat a control diet for 3 days.
The dietary interventions will be spaced 1 week apart.
The ketone supplement drink (Kenetik, Vitanav inc, Washington DC) is a dietary supplement that has been extensively studied in humans and is designated by the FDA as Generally Recognized as Safe (GRAS).
Its use in this study is experimental.
On the day of the 3 labs visits days, magnetic resonance imaging (MRI) will be used to study the brain.
Specifically, levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA.
Following the scans, participants will be provided a dose of alcohol that will elevate participants breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Timothy S Pond, MPH
- Phone Number: 215-746-1959
- Email: timpond@upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania Center for Studies of Addiction
-
Sub-Investigator:
- Henry R. Kranzler, M.D.
-
Sub-Investigator:
- Kyle Kampman, M.D.
-
Contact:
- Timothy S. Pond, M.P.H.
- Phone Number: 215-746-1959
- Email: timpond@pennmedicine.upenn.edu
-
Principal Investigator:
- Corinde Wiers, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Willingness to provide signed, informed consent and commit to completing study procedures.
- Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.
Exclusion Criteria:
- Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.
- Current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.
- Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)
- Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).
- A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).
- Currently suffering from or has a history of stroke and/or stroke related spasticity.
- Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).
- Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).
- Females who are pregnant or breast-feeding
- Contraindication to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his/ her back for up to 2 hrs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketogenic diet
Eat a ketogenic diet for 3 days
|
After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Other Names:
|
Placebo Comparator: Control Diet
Eat a control diet for 3 days
|
After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Other Names:
|
Experimental: Ketone supplement
Eat a control diet for 3 days with a ketone supplement drink
|
After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Other Names:
Control Diet breakfast, lunch, and dinner for 3 days.
Other Names:
|
Experimental: Alcohol Intervention
Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
|
Control Diet breakfast, lunch, and dinner for 3 days.
Other Names:
Ketone supplement 3x day with control diet for 3 days.
Other Names:
Ketogenic Diet breakfast, lunch, and dinner for 3 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in breath alcohol concentration
Time Frame: 3 hours
|
Breath alcohol concentration measured in mg/L of air.
The range is .000 to .400
g/L.
Change in breath alcohol concentration, pre to post alcohol consumption after 3 day diet intervention during lab day.
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in motor agility tasks
Time Frame: 3 hours
|
Motor agility will be assessed with the grooved pegboard task, in which participants will place pegs onto a metal surface containing 25 keyhole-shaped holes that differ in orientation.
Measured in seconds, range 0 to 5 minutes.
Change in motor agility tasks pre to post alcohol consumption after 3 day diet intervention.
|
3 hours
|
Change in cognitive performance tasks
Time Frame: 3 hours
|
Cognitive performance will be measured with a cued go/no-go task, in which participants will press a computer keyboard key in response to a "go" target and suppress the action in response to a "no-go" target.
Measured in % correct responses 0-100.
Pre to post alcohol consumption after 3 day diet intervention.
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kyle Kampman, MD, University of Pennsylvania
- Principal Investigator: Corinde Wiers, Ph.D., University of Pennsylvania
- Study Director: Henry Kranzler, MD, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
September 20, 2023
First Submitted That Met QC Criteria
September 29, 2023
First Posted (Actual)
October 4, 2023
Study Record Updates
Last Update Posted (Actual)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Metabolic Diseases
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Acid-Base Imbalance
- Acidosis
- Alcohol Drinking
- Ketosis
- Alcoholic Intoxication
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Central Nervous System Depressants
- Ethanol
Other Study ID Numbers
- 853707
- 24446 (Other Grant/Funding Number: UPenn ITMAT)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
Boston University Charles River CampusRecruiting
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
University of ArkansasRecruitingDrinking Behavior | Drinking Excessive | DrinkingUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Active, not recruiting
-
University of North Texas Health Science CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Universidad de GranadaCompletedExercise | Drinking, AlcoholSpain
-
Lehigh UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Brown UniversityCompletedCollege DrinkingUnited States
Clinical Trials on Ethanol
-
Parc de Salut MarCompletedHealthy | Alcohol ConsumptionSpain
-
Virginia Commonwealth UniversityU.S. Department of JusticeRecruitingElectronic Cigarette UseUnited States
-
Yale UniversityVA Connecticut Healthcare SystemCompleted
-
Beth Israel Deaconess Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Virginia Commonwealth UniversityU.S. Department of JusticeCompleted
-
Merck Sharp & Dohme LLCCompleted
-
University of NebraskaWithdrawnShort Bowel Syndrome | Blood Stream InfectionsUnited States
-
National Institute of Diabetes and Digestive and...CompletedType 2 Diabetes, Insulin RequiringUnited States
-
Indonesia UniversityNetherlands: Ministry of Health, Welfare and SportsCompleted
-
OrfagenFDA Office of Orphan Products DevelopmentCompletedCongenital Venous MalformationUnited States, France